CD274 and cancer: Impassion130 trial55, which resulted in FDA approval of anti-PD-L1 antibody for TNBCs, demonstrated a significantly improved objective response rate, median progression-free survival, and OS in the PD-L1 positive cohort, similar to other cancer types56–58.